Latest Insider Transactions at Alpine Immune Sciences, Inc. (ALPN)
This section provides a real-time view of insider transactions for Alpine Immune Sciences, Inc. (ALPN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALPINE IMMUNE SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALPINE IMMUNE SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+50.0%
|
$9,000
$5.02 P/Share
|
|
Dec 15
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
45,387
-100.0%
|
$862,353
$19.09 P/Share
|
|
Dec 15
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,387
+50.0%
|
$226,935
$5.02 P/Share
|
|
Dec 14
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
11,600
-100.0%
|
$220,400
$19.0 P/Share
|
|
Dec 14
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,600
+50.0%
|
$58,000
$5.02 P/Share
|
|
Dec 12
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
41,063
-100.0%
|
$698,071
$17.32 P/Share
|
|
Dec 12
2023
|
Mitchell Gold Executive Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,613
+50.0%
|
$0
$0.45 P/Share
|
|
Dec 11
2023
|
James N Topper Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
145,251
+8.18%
|
$1,743,012
$12.74 P/Share
|
|
Dec 11
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
68,870
-67.97%
|
$1,170,790
$17.26 P/Share
|
|
Dec 08
2023
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
8,067
-7.37%
|
$137,139
$17.08 P/Share
|
|
Dec 06
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
6,446
-100.0%
|
$103,136
$16.08 P/Share
|
|
Dec 06
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,446
+50.0%
|
$19,338
$3.23 P/Share
|
|
Dec 05
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
418
-100.0%
|
$6,688
$16.01 P/Share
|
|
Dec 05
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
418
+50.0%
|
$1,254
$3.23 P/Share
|
|
Dec 04
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
63,947
-100.0%
|
$1,023,152
$16.06 P/Share
|
|
Dec 04
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,947
+50.0%
|
$191,841
$3.23 P/Share
|
|
Nov 30
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
700
-100.0%
|
$11,200
$16.0 P/Share
|
|
Nov 30
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+50.0%
|
$2,100
$3.23 P/Share
|
|
Nov 09
2023
|
Xiangmin Cui Director |
BUY
Open market or private purchase
|
Indirect |
375,000
+17.77%
|
$4,500,000
$12.5 P/Share
|
|
Nov 09
2023
|
Decheng Capital Global Healthcare Fund (Master), LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
375,000
+17.77%
|
$4,500,000
$12.5 P/Share
|
|
Nov 06
2023
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
18,003
-100.0%
|
$288,048
$16.03 P/Share
|
|
Nov 06
2023
|
James Paul Rickey Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,989
+37.9%
|
$32,967
$3.23 P/Share
|
|
Sep 23
2022
|
Xiangmin Cui Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,000,000
+30.34%
|
$14,000,000
$7.35 P/Share
|
|
Sep 23
2022
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
1,360,544
+50.0%
|
$9,523,808
$7.35 P/Share
|
|
Sep 23
2022
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Direct |
639,456
+10.68%
|
$4,476,192
$7.35 P/Share
|
|
Jul 15
2022
|
Jay Venkatesan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,063
+7.77%
|
$0
$0.45 P/Share
|
|
Feb 11
2022
|
Frazier Life Sciences Viii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
112,665
+7.06%
|
$788,655
$7.1 P/Share
|
|
Dec 31
2021
|
James Paul Rickey Officer |
SELL
Open market or private sale
|
Direct |
17,013
-70.81%
|
$221,169
$13.92 P/Share
|
|
Sep 23
2021
|
Christopher Peetz Director |
BUY
Open market or private sale
|
Indirect |
1,900
+50.0%
|
$19,000
$10.17 P/Share
|
|
Sep 23
2021
|
Robert E Conway Director |
BUY
Open market or private sale
|
Indirect |
15,000
+23.08%
|
$150,000
$10.08 P/Share
|
|
Sep 21
2021
|
Robert E Conway Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+22.22%
|
$90,000
$9.8 P/Share
|
|
Sep 17
2021
|
Frazier Life Sciences Viii, L.P. > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,200,000
-46.67%
|
-
|
|
Sep 17
2021
|
Xiangmin Cui Director |
BUY
Open market or private purchase
|
Indirect |
1,542,553
+24.68%
|
$13,882,977
$9.4 P/Share
|
|
Sep 17
2021
|
Jay Venkatesan Director |
SELL
Open market or private sale
|
Indirect |
400,000
-13.33%
|
$3,600,000
$9.4 P/Share
|
|
Sep 17
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
45,262
-29.27%
|
$452,620
$10.01 P/Share
|
|
Sep 17
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Indirect |
400,000
-13.33%
|
$3,600,000
$9.4 P/Share
|
|
Sep 17
2021
|
Alpine Immuno Sciences, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
400,000
-13.33%
|
$3,600,000
$9.4 P/Share
|
|
Sep 17
2021
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
1,010,637
+31.9%
|
$9,095,733
$9.4 P/Share
|
|
Sep 17
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,010,637
+31.9%
|
$9,095,733
$9.4 P/Share
|
|
Sep 17
2021
|
Decheng Capital China Life Sciences Usd Fund Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,542,553
+24.68%
|
$13,882,977
$9.4 P/Share
|
|
Sep 16
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
6,768
-4.19%
|
$67,680
$10.0 P/Share
|
|
Sep 15
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
3,484
-2.11%
|
$34,840
$10.0 P/Share
|
|
Jun 28
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
3,479
-2.07%
|
$34,790
$10.0 P/Share
|
|
Jun 25
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
9,473
-5.33%
|
$94,730
$10.01 P/Share
|
|
May 20
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
1,221
-0.68%
|
$18,315
$15.0 P/Share
|
|
May 19
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
50,965
-22.15%
|
$764,475
$15.03 P/Share
|
|
May 13
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-4.17%
|
$110,000
$11.52 P/Share
|
|
May 12
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-4.0%
|
$110,000
$11.68 P/Share
|
|
Apr 14
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.85%
|
$100,000
$10.52 P/Share
|
|
Apr 13
2021
|
Mitchell Gold Executive Chairman and CEO |
SELL
Open market or private sale
|
Direct |
10,000
-3.7%
|
$100,000
$10.07 P/Share
|